Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : TMS-007
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Biogen
Deal Size : $353.0 million
Deal Type : Acquisition
Details : Biogen exercised its option to acquire TMS-007, an investigational drug for acute ischemic stroke, from TMS. Biogen’s decision to acquire TMS-007 was based on positive data from a Phase 2a study.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
May 12, 2021
Lead Product(s) : TMS-007
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Biogen
Deal Size : $353.0 million
Deal Type : Acquisition
Reset All
